A study, using experimental autoimmune encephalomyelitis of mice, a rodent model of human MS, has shown that inhibition of the P2X7 receptor using selective antagonists can reduce demyelination as well as improving MS-associated neurological deficits, thus providing strong evidence to support a role for the P2X7 receptor in the pathogenesis of MS [91]. Here, P2RX7 is linked to myeloid sarcoma.